Which has preferable valuation & earnings, NRIX or LNTH?

Lantheus has higher revenue and earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nurix Therapeutics $83.98M 19.07 -$264.46M -$3.16 N/A Lantheus $1.54B 4.24 $233.56M $4.15 24.19

Is NRIX or LNTH more profitable?

Lantheus has a net margin of 18.05% compared to Nurix Therapeutics' net margin of -411.37%. Lantheus' return on equity of 29.32% beat Nurix Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Nurix Therapeutics -411.37% -64.21% -48.44% Lantheus 18.05% 29.32% 15.00%

Nurix Therapeutics (NRIX) Competitors

$15.48 -0.89 (-5.41%)

Closing price 03:58 PM Eastern

Extended Trading

$15.46 -0.02 (-0.16%)

As of 04:01 PM Eastern

Compare

NRIX vs. IMVT, LNTH, KYMR, PTGX, and SYRE

Should you buy Nurix Therapeutics stock or one of its competitors? MarketBeat compares Nurix Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nurix Therapeutics include Immunovant (IMVT), Lantheus (LNTH), Kymera Therapeutics (KYMR), Protagonist Therapeutics (PTGX), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry.

How does Nurix Therapeutics compare to Immunovant?

Nurix Therapeutics (NASDAQ:NRIX) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

Nurix Therapeutics presently has a consensus price target of $30.46, suggesting a potential upside of 96.72%. Immunovant has a consensus price target of $37.33, suggesting a potential upside of 19.94%. Given Nurix Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Nurix Therapeutics is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

In the previous week, Immunovant had 7 more articles in the media than Nurix Therapeutics. MarketBeat recorded 8 mentions for Immunovant and 1 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 1.89 beat Immunovant's score of 0.35 indicating that Nurix Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Nurix Therapeutics	Very Positive
Immunovant	Neutral

47.1% of Immunovant shares are held by institutional investors. 6.7% of Nurix Therapeutics shares are held by insiders. Comparatively, 1.8% of Immunovant shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Nurix Therapeutics has a beta of 1.86, meaning that its stock price is 86% more volatile than the broader market. Comparatively, Immunovant has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market.

Nurix Therapeutics has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$83.98M	19.07	-$264.46M	-$3.16	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A

Immunovant has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -411.37%. Nurix Therapeutics' return on equity of -64.21% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-411.37%	-64.21%	-48.44%
Immunovant	N/A	-65.66%	-59.88%

Summary

Nurix Therapeutics beats Immunovant on 12 of the 16 factors compared between the two stocks.

How does Nurix Therapeutics compare to Lantheus?

Nurix Therapeutics (NASDAQ:NRIX) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

99.1% of Lantheus shares are held by institutional investors. 6.7% of Nurix Therapeutics shares are held by company insiders. Comparatively, 1.7% of Lantheus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Nurix Therapeutics presently has a consensus target price of $30.46, suggesting a potential upside of 96.72%. Lantheus has a consensus target price of $101.86, suggesting a potential upside of 1.44%. Given Nurix Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Nurix Therapeutics is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Lantheus has higher revenue and earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$83.98M	19.07	-$264.46M	-$3.16	N/A
Lantheus	$1.54B	4.24	$233.56M	$4.15	24.19

Lantheus has a net margin of 18.05% compared to Nurix Therapeutics' net margin of -411.37%. Lantheus' return on equity of 29.32% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-411.37%	-64.21%	-48.44%
Lantheus	18.05%	29.32%	15.00%

Nurix Therapeutics has a beta of 1.86, indicating that its share price is 86% more volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, indicating that its share price is 103% less volatile than the broader market.

In the previous week, Lantheus had 5 more articles in the media than Nurix Therapeutics. MarketBeat recorded 6 mentions for Lantheus and 1 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 1.89 beat Lantheus' score of 0.44 indicating that Nurix Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Nurix Therapeutics	Very Positive
Lantheus	Neutral

Summary

Lantheus beats Nurix Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Nurix Therapeutics compare to Kymera Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.

Nurix Therapeutics has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$83.98M	19.07	-$264.46M	-$3.16	N/A
Kymera Therapeutics	$39.21M	153.52	-$311.35M	-$3.57	N/A

Nurix Therapeutics has a beta of 1.86, suggesting that its share price is 86% more volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.02, suggesting that its share price is 102% more volatile than the broader market.

Nurix Therapeutics has a net margin of -411.37% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-411.37%	-64.21%	-48.44%
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

In the previous week, Kymera Therapeutics had 7 more articles in the media than Nurix Therapeutics. MarketBeat recorded 8 mentions for Kymera Therapeutics and 1 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 1.89 beat Kymera Therapeutics' score of 0.64 indicating that Nurix Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Nurix Therapeutics	Very Positive
Kymera Therapeutics	Positive

Nurix Therapeutics currently has a consensus price target of $30.46, suggesting a potential upside of 96.72%. Kymera Therapeutics has a consensus price target of $118.10, suggesting a potential upside of 61.38%. Given Nurix Therapeutics' higher probable upside, analysts plainly believe Nurix Therapeutics is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.95

Summary

Nurix Therapeutics and Kymera Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Nurix Therapeutics compare to Protagonist Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

Nurix Therapeutics has a beta of 1.86, suggesting that its share price is 86% more volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.85, suggesting that its share price is 85% more volatile than the broader market.

Protagonist Therapeutics has a net margin of -154.88% compared to Nurix Therapeutics' net margin of -411.37%. Protagonist Therapeutics' return on equity of -17.76% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-411.37%	-64.21%	-48.44%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

Nurix Therapeutics presently has a consensus price target of $30.46, suggesting a potential upside of 96.72%. Protagonist Therapeutics has a consensus price target of $115.21, suggesting a potential upside of 20.85%. Given Nurix Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Nurix Therapeutics is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Protagonist Therapeutics has lower revenue, but higher earnings than Nurix Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$83.98M	19.07	-$264.46M	-$3.16	N/A
Protagonist Therapeutics	$46.02M	133.23	-$130.15M	-$1.81	N/A

In the previous week, Protagonist Therapeutics had 7 more articles in the media than Nurix Therapeutics. MarketBeat recorded 8 mentions for Protagonist Therapeutics and 1 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 1.89 beat Protagonist Therapeutics' score of 0.72 indicating that Nurix Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Nurix Therapeutics	Very Positive
Protagonist Therapeutics	Positive

98.6% of Protagonist Therapeutics shares are owned by institutional investors. 6.7% of Nurix Therapeutics shares are owned by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Protagonist Therapeutics beats Nurix Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Nurix Therapeutics compare to Spyre Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and Spyre Therapeutics (NASDAQ:SYRE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

In the previous week, Spyre Therapeutics had 3 more articles in the media than Nurix Therapeutics. MarketBeat recorded 4 mentions for Spyre Therapeutics and 1 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 1.89 beat Spyre Therapeutics' score of 1.27 indicating that Nurix Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Nurix Therapeutics	Very Positive
Spyre Therapeutics	Positive

Nurix Therapeutics currently has a consensus price target of $30.46, suggesting a potential upside of 96.72%. Spyre Therapeutics has a consensus price target of $90.25, suggesting a potential upside of 22.68%. Given Nurix Therapeutics' higher probable upside, equities research analysts plainly believe Nurix Therapeutics is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

80.4% of Spyre Therapeutics shares are held by institutional investors. 6.7% of Nurix Therapeutics shares are held by company insiders. Comparatively, 15.7% of Spyre Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Nurix Therapeutics has a beta of 1.86, suggesting that its share price is 86% more volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.05, suggesting that its share price is 205% more volatile than the broader market.

Spyre Therapeutics has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -411.37%. Spyre Therapeutics' return on equity of -42.88% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-411.37%	-64.21%	-48.44%
Spyre Therapeutics	N/A	-42.88%	-27.76%

Spyre Therapeutics has lower revenue, but higher earnings than Nurix Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$83.98M	19.07	-$264.46M	-$3.16	N/A
Spyre Therapeutics	$890K	7,178.16	-$155.20M	-$2.08	N/A

Summary

Spyre Therapeutics beats Nurix Therapeutics on 12 of the 17 factors compared between the two stocks.

Get Nurix Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NRIX vs. The Competition

Export

Metric	Nurix Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.60B	$3.28B	$6.25B	$12.42B
Dividend Yield	N/A	2.33%	2.69%	5.29%
P/E Ratio	-4.90	17.91	22.28	24.19
Price / Sales	19.07	324.60	581.86	138.32
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	2.93	6.64	9.84	6.72
Net Income	-$264.46M	$24.20M	$3.57B	$337.19M
7 Day Performance	-11.36%	-3.17%	-1.15%	0.53%
1 Month Performance	-7.88%	0.57%	3.85%	5.10%
1 Year Performance	28.19%	47.29%	27.43%	34.36%

Nurix Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NRIX Nurix Therapeutics	2.8828 of 5 stars	$15.49 -5.4%	$30.46 +96.7%	+34.8%	$1.60B	$83.98M	N/A	300
IMVT Immunovant	2.507 of 5 stars	$32.86 -1.3%	$37.33 +13.6%	+100.6%	$6.75B	N/A	N/A	120
LNTH Lantheus	2.2554 of 5 stars	$97.13 -2.2%	$101.86 +4.9%	+24.9%	$6.47B	$1.55B	23.40	1,193
KYMR Kymera Therapeutics	2.2548 of 5 stars	$78.47 -3.6%	$118.10 +50.5%	+65.3%	$6.45B	$51.48M	N/A	170
PTGX Protagonist Therapeutics	2.6064 of 5 stars	$94.92 -4.7%	$115.21 +21.4%	+85.8%	$6.40B	$74.06M	N/A	120	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NRIX) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nurix Therapeutics (NRIX) Competitors

NRIX vs. IMVT, LNTH, KYMR, PTGX, and SYRE

How does Nurix Therapeutics compare to Immunovant?

Summary

How does Nurix Therapeutics compare to Lantheus?

Summary

How does Nurix Therapeutics compare to Kymera Therapeutics?

Summary

How does Nurix Therapeutics compare to Protagonist Therapeutics?

Summary

How does Nurix Therapeutics compare to Spyre Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRIX vs. The Competition

Nurix Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nurix Therapeutics (NRIX) Competitors

NRIX vs. IMVT, LNTH, KYMR, PTGX, and SYRE

How does Nurix Therapeutics compare to Immunovant?

Do analysts recommend NRIX or IMVT?

Does the media favor NRIX or IMVT?

Do institutionals & insiders have more ownership in NRIX or IMVT?

Which has more risk & volatility, NRIX or IMVT?

Which has preferable earnings and valuation, NRIX or IMVT?

Is NRIX or IMVT more profitable?

Summary

How does Nurix Therapeutics compare to Lantheus?

Do institutionals and insiders have more ownership in NRIX or LNTH?

Do analysts prefer NRIX or LNTH?

Which has preferable valuation & earnings, NRIX or LNTH?

Is NRIX or LNTH more profitable?

Which has more risk & volatility, NRIX or LNTH?

Does the media prefer NRIX or LNTH?

Summary

How does Nurix Therapeutics compare to Kymera Therapeutics?

Which has better earnings and valuation, NRIX or KYMR?

Which has more volatility & risk, NRIX or KYMR?

Is NRIX or KYMR more profitable?

Does the media prefer NRIX or KYMR?

Do analysts rate NRIX or KYMR?

Summary

How does Nurix Therapeutics compare to Protagonist Therapeutics?

Which has more volatility & risk, NRIX or PTGX?

Is NRIX or PTGX more profitable?

Do analysts recommend NRIX or PTGX?

Which has better valuation & earnings, NRIX or PTGX?

Does the media prefer NRIX or PTGX?

Do insiders & institutionals have more ownership in NRIX or PTGX?

Summary

How does Nurix Therapeutics compare to Spyre Therapeutics?

Does the media favor NRIX or SYRE?

Do analysts rate NRIX or SYRE?

Do insiders and institutionals have more ownership in NRIX or SYRE?

Which has more risk & volatility, NRIX or SYRE?

Is NRIX or SYRE more profitable?

Which has preferable valuation & earnings, NRIX or SYRE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRIX vs. The Competition

Nurix Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools